{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T08:02:15Z","timestamp":1749888135664,"version":"3.40.5"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:p>Eosinophilic infiltration is sometimes observed histologically in ulcerative colitis (UC), but the effect of the degree of infiltration on the treatment course for UC is not completely understood. We investigated whether short-term steroid administration in UC patients refractory to maintenance therapy, with high eosinophilic infiltration in the colonic mucosa, contributed to the clinical and endoscopic improvement. Ten patients with endoscopically active and pathologically high eosinophilic infiltration, based on pathological examination using endoscopic biopsy, were examined for the clinical background when starting steroid treatment. The clinical and endoscopic improvement before and after steroid use were assessed prospectively. The average initial steroid dosage and duration of use were 21.0\u2009mg and 102.7 days, respectively. The mean values before and after steroid use of the clinical activity index, the Mayo endoscopic subscore, and the UC endoscopic index of severity were 2.4 and 1.0, 1.8 and 0.7, and 3.9 and 1.1, respectively. All scores improved significantly after steroid use (<jats:italic toggle=\"yes\">P<\/jats:italic> = .042, <jats:italic toggle=\"yes\">P<\/jats:italic> = .002, <jats:italic toggle=\"yes\">P<\/jats:italic> = .002, respectively). Steroids were discontinued in all patients; no patients required steroid re-administration. There may be cases of UC with eosinophilic infiltration into the colonic mucosa and resistance to maintenance treatment, suggesting that short-term steroid administration may contribute to clinical and endoscopic improvements.<\/jats:p>","DOI":"10.1097\/md.0000000000031017","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T15:23:36Z","timestamp":1665415416000},"page":"e31017","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study"],"prefix":"10.1097","volume":"101","author":[{"given":"Takahiro","family":"Miyazu","sequence":"first","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Ishida","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Asai","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[{"name":"Department of Endoscopic and Photodynamic Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[{"name":"Center for Clinical Research, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Baba","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-1097","authenticated-orcid":false,"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Hamamatsu University School of Medicine, Handayama, Higashi-ku, Hamamatsu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","article-title":"Targeting immune cell circuits and trafficking in inflammatory bowel disease.","volume":"20","author":"Neurath","year":"2019","journal-title":"Nat Immunol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2015.07.008","article-title":"Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis.","volume":"43","author":"Griseri","year":"2015","journal-title":"Immunity"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"O420","DOI":"10.1111\/codi.12725","article-title":"Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.","volume":"16","author":"Zezos","year":"2014","journal-title":"Colorectal Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/ibd\/izz251","article-title":"Mucosal eosinophilia is an independent predictor of vedolizumab efficacy in inflammatory bowel diseases.","volume":"26","author":"Kim","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/ibd\/izaa225","article-title":"Improvement in ulcerative colitis by administration of Benralizumab for comorbid refractory bronchial asthma: a novel clinical observation.","volume":"27","author":"Sugimoto","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma.","volume":"29","author":"D\u00e1vila Gonz\u00e1lez","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2169\/internalmedicine.4554-20","article-title":"Eosinophilic gastroenteritis in an ulcerative colitis patient during treatment with tumor necrosis factor-alpha antagonist.","volume":"59","author":"Hayashida","year":"2020","journal-title":"Intern Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","article-title":"Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.","volume":"298","author":"Rachmilewitz","year":"1989","journal-title":"BMJ"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease.","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/gut.2003.024190","article-title":"T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn\u2019s disease.","volume":"53","author":"Matsuoka","year":"2004","journal-title":"Gut"},{"key":"R18-20250504","first-page":"300","article-title":"Cytokines, chemokine receptors, and homing molecule distribution in the rectum and stomach of pediatric patients with ulcerative colitis.","volume":"37","author":"Berrebi","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1046\/j.1365-2249.1998.00532.x","article-title":"Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn\u2019s disease (CD).","volume":"111","author":"Giacomelli","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00054725-200409000-00002","article-title":"Prospective evaluation of intestinal homing memory T cells in ulcerative colitis.","volume":"10","author":"Hart","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R21-20250504","first-page":"967","article-title":"Multigene analysis unveils distinctive expression profiles of helper T-cell-related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn\u2019s disease.","volume":"20","author":"Iboshi","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1111\/j.1572-0241.1999.01372.x","article-title":"Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity.","volume":"94","author":"Inoue","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1046\/j.1440-1746.2003.03088.x","article-title":"Differential expression of CCR5 and CRTH2 on infiltrated cells in colonic mucosa of patients with ulcerative colitis.","volume":"18","author":"Matsuzaki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00054725-199603000-00004","article-title":"Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles.","volume":"2","author":"Mullin","year":"1996","journal-title":"Inflamm Bowel Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1442-200X.2009.03019.x","article-title":"Increased mucosal expression of GATA-3 and STAT-4 in pediatric ulcerative colitis.","volume":"52","author":"Ohtani","year":"2010","journal-title":"Pediatr Int"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000445133","article-title":"The role of T-cell subsets in chronic inflammation in celiac disease and inflammatory bowel disease patients: more common mechanisms or more differences?","volume":"1","author":"Hisamatsu","year":"2016","journal-title":"Inflamm Intest Dis"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri.2017.90","article-title":"Type 2 immunity in tissue repair and fibrosis.","volume":"18","author":"Gieseck","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.","volume":"64","author":"Reinisch","year":"2015","journal-title":"Gut"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab.","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:41:03Z","timestamp":1746333663000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000031017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":29,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000031017","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}